Essential Hypertension
Conditions
Keywords
Grade 1 Hypertension, primary hypertension, hibiscus, olive leaves, medicinal plants, blood pressure
Brief summary
In this Phase III clinical trial, researchers evaluate the efficacy and safety of NW Roselle®, a powdered medicinal product developed by Natural Wellness. NW Roselle combines extracts from Hibiscus Sabdariffa (HS) flowers and Olea europaea (OE) leaves. The trial aims to gather evidence on the efficacy and safety of NW Roselle as a potential treatment option for Grade 1 essential hypertension.
Detailed description
Hypertension is a major risk factor for heart, brain, and kidney diseases, and is a leading cause of death and illness globally. Natural Wellness has developed NW Roselle®, a powdered medicinal product that combines extracts from Hibiscus Sabdariffa (HS) flowers and Olea europaea (OE) leaves. In this Phase III clinical trial, researchers are evaluating the efficacy and safety of NW Roselle, in the treatment of Grade 1 essential hypertension. Eligible participants who meet the criteria will be enrolled and randomized in a 1:1 ratio. They will be assigned to receive either NW Roselle or an active control, Captopril 25 mg twice daily. Before the treatment begins, participants will provide informed consent and undergo assessments to collect information about their medical history, hypertension status, lifestyle factors, and demographics. Throughout the trial, the participant's vital signs, physical exams, and laboratory tests will be conducted to monitor their health and response to the treatment. Adherence to the assigned treatment will be monitored, and any potential adverse events or side effects will be tracked.
Interventions
DRUGNW Roselle
NW Roselle is a powdered extract from the flowers of Hibiscus Sabdariffa (300mg) and the leaves of Olea europaea (200 mg).
Active Comparator
Sponsors
Natural Wellness Egypt
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
A Phase III, Randomized, Parallel, Double-Dummy, Active-Controlled Clinical Trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosed with grade 1 essential hypertension (Systolic Blood Pressure: 140-159 mmHg, and/or Diastolic Blood Pressure 90-99 mmHg) (Williams et al., 2018). 2. Not currently taking any medication for hypertension. 3. Able and willing to provide written informed consent.
Exclusion criteria
1. Pregnant or lactating women. 2. Patients with BMI \> 45 Kg/m2 or BMI \< 18 Kg/m2. 3. Patients with a known history of secondary hypertension (e.g., hyperaldosteronism, pheochromocytoma, renal artery stenosis, Cushing syndrome). 4. Renal impairment (Estimated Creatinine Clearance (Cr.Cl.) \< 30 ml/min as measured by the Cockcroft-Gault formula). 5. Known Severe hepatic impairment, biliary cirrhosis, or cholestasis. 6. Patients with a history of arrhythmias, ischemic heart diseases, obstruction of the outflow tract of the left ventricle (e.g., hypertrophic obstructive cardiomyopathy, and high-grade aortic stenosis), congestive heart failure, valvular disease, myocardial infarction (MI), angina, myocardial revascularization, or cerebrovascular accident (CVA) within 6 months prior to study entry. 7. Participation in other clinical studies within 30 days before screening. 8. Known or suspected allergy or any contraindications to the trial products.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The mean systolic blood pressure | Week 12 | The mean systolic blood pressure difference between the study arm and the control arm adjusted for baseline blood pressure. |
| The mean diastolic blood pressure | Week 12 | The mean diastolic blood pressure difference between the study arm and the control arm adjusted for baseline blood pressure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Systolic Blood Pressure Paired Change | Week 12 | The mean changes in systolic blood pressure between baseline and week 12 within each arm. |
| Diastolic Blood Pressure Paired Change | Week 12 | The mean changes in diastolic blood pressure between baseline and week 12 within each arm. |
| The rate of achieving blood pressure levels of (Systolic < 140 and Diastolic < 90 mmHg) by week 12 | Week 12 | The proportion of patients in each treatment group who are able to achieve the target blood pressure levels of systolic blood pressure \< 140 mmHg and diastolic blood pressure \< 90 mmHg by week 12. |
| The rate of achieving systolic blood pressure range (120-130 mmHg) by week 12 | Week 12 | The proportion of patients in each treatment group who are able to achieve the target systolic blood pressure range of 120-130 mmHg by week 12. |
| The rate of achieving diastolic blood pressure range (70 - 80 mmHg) by week 12 | Week 12 | The proportion of patients in each treatment group who are able to achieve the target diastolic blood pressure control of 70-80 mmHg by week 12. |
| Compliance Rate | 12 weeks | The mean medication compliance rate (%) will be calculated for each subject as: \[(Total number of administered doses) / (Expected number of doses)\] \*100%. |
| Adverse events rate | 12 weeks | 2\. The incidence of AEs reported by the patients, summarized by system organ class, severity, and relationship to study intervention, over the course of treatment. |
Contacts
Primary ContactTarek Nassar, MSc
Backup ContactSylvia Samir, MSc
Outcome results
None listed